She continued, saying that, "in addition to lysosomal storage disorders (lysosomal genetic deficiency), other diseases related to prematurity, gestational diabetes, pain, cancer, and DNA damages could be assessed with metabolic fingerprints or profiles."
"Waters Corporation is dedicated to the implementation of mass spectrometry in a clinical setting. The high quality of research being done at CHUS by Dr. Auray-Blais into metabolic disorders will eventually lead to more widespread use of mass spectrometry as a diagnostic tool, resulting in better and earlier diagnosis of these diseases and having a significant positive impact on the quality of life of the patients," added Dr. Mike Morris, Director of Technology and Business Development, Clinical Operations Group, Waters Division.
"Through the work at the Centre de recherche clinique Etienne-Le Bel,
the CHUS remains at the forefront of innovative research into hereditary
metabolic disorders and medical genetics. The creation of this center of
expertise dedicated to mass-spectrometry research allows us to become a
technology showcase for research and clinical practice in this field.
Research and knowledge development are essential elements in improving the
care delivered to patients. This stands out today as a superb example of a
strong, profitable partnership with Waters, a company that also has at
heart the wellness of the population and is fully aware of the importance
of the role that it can play as a catalyst," stated Patricia Gauthier, CHUS
Waters, Synapt, and Quattro ar
|SOURCE Sherbrooke Hospital|
Copyright©2008 PR Newswire.
All rights reserved